RBC Capital lowered the firm’s price target on Aardvark Therapeutics (AARD) to $19 from $20 and keeps an Outperform rating on the shares after its Q2 results. The quarter contained a few timeline slippages as the go-forward clinical plans take clearer shape, most notably the highly-anticipated Prader-Willi phase 3 for ‘101 now expected in Q3 of 2026 vs. early-2026 previously, though incorporation of pediatric patients in that study may help increase potential effect size and probability of success, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)
- Buy Rating for Aardvark Therapeutics, Inc. Driven by Promising ARD-201 Obesity Treatment Potential
- Aardvark Therapeutics Reveals Promising Preclinical Data for ARD-201
- Aardvark Therapeutics announces preclinical data on ARD-201
- Aardvark Therapeutics announces inducement grants under Nasdaq listing rule